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152 H.H. Baghdadi et al.to determine the levels of plasma homocysteine and antioxidant enzymes in male rats given ED drugs.
Methods: Male rats were given a daily dose of 1.48 mg/kg body weight sildenafil citrate (Viagra), 0.285 mg/kg vardenafil
(Levitra) or 0.285 mg/kg tadalafil (Cialis) for 3 weeks, and plasma levels of homocysteine, SOD and catalase were measured;
high- and low-density lipoproteins, total cholesterol and triglycerides were also determined.
Results: The level of homocysteine was increased by 93% and 67% in plasma of sildenafil- and vardenafil-treated rats, respec-
tively, whereas tadalafil did not change the level significantly. Sildenafil and vardenafil also increased SOD activity by 35% and
46%, respectively; and sildenafil, vardenafil and tadalafil increased the activity of catalase by 33%, 50% and 43%, respectively.
A nonsignificant increase in the level of total cholesterol was seen after treatment with all the drugs, and sildenafil, vardenafil
and tadalafil increased the levels of high-density lipids by 25%, 41%, and 25%, respectively.
Conclusion: The ED medications sildenafil and vardenafil increase the levels of homocysteine and antioxidant enzyme activities.
Tadalafil appeared to be safer than the other two drugs, as it did not change the level of homocysteine. Patients taking sildenafil or
vardenafil should therefore be advised to take vitamin B12 and folic acid in order to reduce the level of homocysteine, as these vita-
mins play an important role in biotransformation of homocysteine into methionine.
Keywords: Catalase; Hyperhomocysteinaemia; Sildenafil citrate; Superoxide dismutase; Tadalafil; Vardenafil
 2013 Taibah University. Production and hosting by Elsevier Ltd. All rights reserved.Introduction
The inability to attain or maintain penile erection sufficient
for satisfactory sexual performance is defined as erectile dys-
function (ED). A class of vasodilator drugs, phosphodiester-
ase type-5 (PDE-5) inhibitors, have been developed for
treatment of ED and are used by millions of men around
the world.1–3 These drugs inhibit PDE-5, which is found in
most vascular beds as well as in cardiac myocytes,4–6 by
increasing cyclic GMP levels in response to nitric oxide, there-
by augmenting the relaxation of smooth muscle tissues.7–9 The
first PDE-5 inhibitor used for the treatment of ED was silde-
nafil citrate (Viagra). Two additional drugs, vardenafil (Lev-
itra) and tadalafil (Cialis) and are also used. Vardenafil
was shown in a rabbit model to increase intracavernosal pres-
sure more quickly and to a greater extent than sildenafil.10,11
The duration of action is similar, but vardenafil is more potent
and more selective biochemically. Tadalafil is long-acting,
being effective for up to 36 h.12,13 A large body of evidence
shows that PDE-5 inhibitors are generally safe, with the
exception of a marked hypotensive effect in men when com-
bined with nitrates and a blockers used to treat essential
hypertension.
Homocysteine is a sulfur-containing amino acid, the metab-
olism of which depends mainly on two pathways: re-methyla-
tion to methionine, which requires folate and vitamin B12, and
trans-sulfuration to cystathionine, which requires pyridoxal-
5-phosphate.14,15 Hyperhomocysteinaemia, a condition that
arises from disrupted homocysteine metabolism, was shown
in epidemiological studies to be associated with an increased
risk for vascular disease.16 Elevated plasma homocysteine con-
centrations in people with homocystinuria were responsible for
the development of premature occlusive vascular disease,17 and
homocysteine–cysteine mixed disulfide was significantly higher
after a methionine load in patients with coronary artery dis-
ease than in controls.18 This finding provided the basis for sub-
sequent studies, culminating in a meta-analysis, published in
1995,19–21 of 27 studies involving more than 4000 patients with
occlusive (cardiovascular, peripheral and cerebrovascular)vascular disease and the same numbers of controls. The results
showed that homocysteine was an independent, graded risk
factor for atherosclerotic disease in the coronary, cerebral
and peripheral vessels. A 5-lM increment in total plasma
homocysteine was associated with increased risks for coronary
heart disease of 60% for men and 80% for women.14,22–24 The
meta-analysis concluded that the risk for arteriosclerotic vas-
cular disease increased with increasing homocysteine level,
regardless of whether cholesterol was normal or elevated.21
Experiments on arterial segments and in experimental animals
as well as observations of hyperhomocysteinaemic patients
have shown that homocysteine can contribute to several pro-
cesses that lead to atherosclerosis.25–28
There is growing interest among researchers about the role
of oxidative stress in the pathophysiological mechanism of
ED.29 Oxidative stress occurs when there is an imbalance be-
tween prooxidants and the ability of antioxidants to scavenge
excess reactive oxygen species.30 The role of oxidative stress
and reactive oxygen species in the pathophysiological mecha-
nisms of male and female infertility has been evaluated exten-
sively;29 however, its role in ED has not been investigated
comprehensively. Both in vitro and in vivo studies have shown
significant associations between the production of reactive
oxygen species and ED, especially in diabetic animal mod-
els,31 and oxidative stress was shown to be involved in
ED.32 Superoxide dismutase (SOD), an antioxidant enzyme
that catalyzes the conversion of superoxide anion to hydro-
gen peroxide and molecular oxygen, is a promising therapeu-
tic target for ED.32
To our knowledge, there have been no studies of the asso-
ciation between treatment with ED medications such as silde-
nafil, vardenafil and tadalafil and plasma homocysteine levels
as an independent risk factor for cardiovascular disease.
Therefore, the present study was carried out to determine
the levels of homocysteine and also of antioxidant enzymes
and other biochemical parameters, including low-density lipo-
proteins (LDL), high-density lipoproteins (HDL), triglycer-
ides and total cholesterol, in the plasma of rats given ED
drugs for 3 weeks.
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Animals
Fifty male Sprague–Dawley rats weighing 200–220 g were ob-
tained from the animal house of the Faculty of Medicine,
Alexandria University, Alexandria, Egypt. The rats were
housed in standard cages and given food and water ad libi-
tum. The local ethics committee of the Institute of Graduate
Studies and Research, Alexandria University, approved the
design of the experiments, and the protocol conformed to
the guidelines of the United States National Institutes of
Health. After a period of acclimatization, the animals were
divided into four groups. One group of 11 rats was used as
control and received ddH2O as vehicle, and groups of 13 rats
were given daily doses of sildenafil (1.48 mg/kg), tadalafil
(0.2 mg/kg) or vardenafil (0.2 mg/kg) for 3 weeks. Sildenafil
(Pfizer), tadalafil (Lilly) and vardenafil (Schering-Plough)
were obtained from local pharmacies in Saudi Arabia. At
the end of the experimental period, the rats were sacrificed
by cervical decapitation after administration of diethyl ether
as anesthetic, and fasting blood samples were collected from
the sacrificed animals in heparinized tubes. Plasma samples
were obtained by centrifugation at 4000 rpm for 20 min and
stored at 80 C until use.
Homocysteine determination
Most homocysteine in plasma is bound to proteins by disul-
fide bonds with thiol-containing residues; oxidized homocys-
teine and homocysteine–cysteine mixed disulfide are also
present. Total homocysteine was measured after reduction
of disulfide bonds and detection of released homocysteine
by use of dithiothreitol. Homocysteine in test samples is con-
verted to S-adenosyl-L-homocysteine (SAH) by use of S-
adenosyl-L-homocysteine hydroxylase and excess adenosine.
The subsequent solid-phase enzyme immunoassay is based
on competition between SAH in the sample and immobilized
SAH bound to the walls of the microtitre plate for binding
sites on a monoclonal anti-SAH antibody. After removal
of anti-SAH antibody not bound to the plate, a secondary
rabbit anti-mouse antibody labeled with horseradish peroxi-
dase is added. Peroxidase activity is measured spectrophoto-
metrically after addition of the substrate, and the absorbance
is inversely related to the concentration of total homocyste-
ine in the sample.33 The full procedure for homocysteine
determination was followed according to the instructions
for the homocysteine enzyme immunoassay kit (Axis-Shield,
Germany).
SOD activity
SOD was measured according to the method of Sun et al.34
with a kit supplied by Randox Laboratory, United Kingdom.
SOD estimation is based on the generation of superoxide rad-
icals produced by xanthine and xanthine oxidase, which react
with nitroblue tetrazolium to form formazin dye. SOD activity
is then measured at 560 nm by the degree of inhibition of this
reaction and expressed as mmol/min per ml of plasma.Catalase activity
Catalase activity was determined by the method by Beers and
Sizer,34 which is based on decreasing absorbance of H2O2 solu-
tion decomposed by the enzyme, with a kit obtained from
Randox Laboratory, United Kingdom. The quantity of
H2O2 decomposed over a specified time is calculated from
the molar absorbance coefficient. Absorbance is measured at
240 nm, and catalase activity is expressed as IU/l of plasma.
Total cholesterol level
Cholesterol was determined enzymatically with cholesterol
esterase and cholesterol oxidase. Cholesterol esters are cleaved
by the action of cholesterol esterase to yield free cholesterol
and free fatty acids. The color intensity is directly proportional
to the concentration of cholesterol and was determined spec-
trophotometrically. The full procedure of cholesterol determi-
nation was followed according to the instructions with the kit
(Biosystems, Barcelona, Spain).
Lipid determinations
Briefly, HDL was measured in the supernatant after precipita-
tion of apolipoprotein B-containing particles with dextran sul-
fate–MgCl2. For LDL, a specific detergent solubilizes the
cholesterol from HDL, very low-density lipoproteins and chy-
lomicrons. The cholesterol esters are broken down by choles-
terol esterase and cholesterol oxidase in a non-color-forming
reaction. The second detergent (MES buffer, > 30 mmol/l,
N,N-bis(4-sulfobutyl)-m-toluidine 1 mmol/l, detergent, pH
6.3) solubilizes cholesterol from LDL in the sample, and
LDL cholesterol is then measured spectrophotometrically at
546 nm.
The method for determining triglycerides is based on use of
a lipoprotein lipase for rapid, complete hydrolysis of triglycer-
ides to yield glycerol, followed by oxidation to dihydroxyace-
tone phosphate and hydrogen peroxide. The hydrogen
peroxide produced reacts with 4-aminophenazone and 4-chlo-
rophenol under the catalytic actions of peroxidase to form a
red color, which is measured spectrophotometrically. The full
procedure for determination of LDL, HDL and triglycerides
was performed according to the manufacturer’s instructions
(Biosystems, Barcelona, Spain).
Statistical analysis
Means and standard errors were calculated. Data were com-
pared with Student’s t test. The level of significance for all
experiments was set at p< 0.05.Results
The results are shown in Table 1. Sildenafil and vardenafil
increased the level of homocysteine in rat plasma by 93%
and 67%, respectively, while tadalafil had no effect. Sildenafil
and vardenafil also increased SOD activity by 35% and 46%,
respectively; and sildenafil, vardenafil and tadalafil increased
Table 1: Changes in levels of homocysteine, superoxide dismutase (SOD), catalase activities and other biochemical parameters after
treatment of male rats with a daily dose of tadalaffil, vardenafil and sildenafil for three weeks.
Biochemical
parameters
Treatments
Control Tadalafil (Cialis) Vardenafil (Levitra) Sildenafil (Viagra)
Homocysteine level
[lM/L]
7.75 ± 0.79 7.78 ± 0.98 [NSp> 0.05]** 12.95 ± 1.77* [+67%, p< 0.05] 14.92 ± 1.788 [+93%, p< 0.05]
SOD activity
[mmol/min/mL]
2.264 ± 0.19 2.613 ± 0.28 [NSp> 0.05] 3.20 ± 0.179* [+42%, p< 0.05] 2.98 ± 0.133* [+32%, p< 0.05]
Catalase activity
[IUnit/L]
168.0 ± 12.9 241.8 ± 13.6* [+43%, p< 0.05] 252.7 ± 21.9* [+50%, p< 0.05] 224.0 ± 16.0* [+33%, p< 0.05]
Total cholesterol
level [mg/DL]
91.7 ± 5.0 101.0 ± 17.1 [NS, p> 0.05] 113.9 ± 6.4 [NS,p> 0.05] 106.2 ± 7.12 [NS,p> 0.05]
HDL [mg/DL] 36.2 ± 2.0 44.4 ± 1.9 [NS,p> 0.05] 51.0 ± 2.1* [+42%, p< 0.05] 44.0 ± 2.18* [+23%,, p< 0.05]
LDL [mg/DL] 69.0 ± 6.8 72.0 ± 5.45 [NS,p> 0.05] 71.8 ± 5.6 [NS,p> 0.05] 71.0 ± 6.9 [NS,p> 0.05]
Triglycerides [mg/DL] 103.0 ± 14.4 89.0 ± 5.4 [NS,p> 0.05] 94.0 ± 5.9 [NS,p> 0.05] 86.0 ± 5.65* [17%, p< 0.05]
Values are expressed as means ± SEM.
NS; Values are not significantly different from the corresponding control value.
* Values are significantly different from the corresponding control value at p< 0.05.
** NS, Values are not significantly different from the corresponding control value at p> 0.05.
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The level of total cholesterol did not change after treatment
of rats with any of the drugs, but sildenafil, vardenafil and
tadalafil increased the levels of HDL by 25%, 41% and
25%, respectively.
Discussion
In this study, the level of homocysteine increased significantly
in rats treated with sildenafil or vardenafil, but tadalafil had no
significant effect, indicating that its mechanism of vasodilata-
tory action is different than those of the other two drugs, per-
haps associated with its prolonged effect. The study suggests,
for the first time, that cardiovascular risk might be increased
after prolonged use of sildenafil or vardenafil, due to increased
homocysteine levels. In support of our suggestion, it has been
shown that hyperhomocysteinaemia caused endothelial dys-
function35–37 in animal models38 and in cell culture.39,40
Homocysteine generates superoxide and hydrogen peroxide,
both of which have been linked to damage of the endothelial
lining of arterial vessels. Moreover, homocysteine changes
the levels of coagulation factors, causing blood clot forma-
tion.26,27,41 In rat aortic smooth muscle cells, homocysteine
was shown to increase DNA synthesis and mRNA levels in cy-
clin D1 and cyclin A, which are important for the re-entry of
these cells into the cell cycle. Furthermore, homocysteine pro-
moted proliferation of the aortic smooth muscle cells.42 The
growth-promoting effect of homocysteine on vascular smooth
muscle cells, together with its inhibitory effect on endothelial
cell growth, represent a possible mechanism for homocyste-
ine-induced atherosclerosis.42,43
The present study showed that sildenafil and vardenafil sig-
nificantly increase the activities of both SOD and catalase.
Other studies also found that sildenafil raised the concentra-
tions of these antioxidants and reduced oxidative stress.44 High
levels of superoxide anion and hydrogen peroxide increase oxi-
dative stress,45 and it is possible that increased SOD and cata-
lase activities are a response to the increased superoxide aniongenerated as a result of increased homocysteine and probably
represent a defense mechanism activated to protect the cell
against an oxidative insult. Quenching of oxidative stress by
sildenafil and vardenafil could sustain the bioavailability of ni-
tric oxide for vasodilatation, which may be another mechanism
of action of ED drugs, as most cases of ED are associated with
oxidative stress.46,47 In support of our new observation, hype-
rhomocysteinaemia was found to increase oxidative stress and
was blocked by induction of SOD by sildenafil.48 Moreover,
sildenafil depresses hydrogen peroxide generation by mimick-
ing SOD and preventing generation of reactive oxygen
species.49,50
It is becoming widely accepted that hypercholesterolaemia
is associated with endothelial dysfunction due to an increase
in superoxide anion production.51,52 In the present study,
however, treatment of rats with ED drugs did not change
the levels of total cholesterol and LDL significantly; however,
the level of HDL increased after treatment with sildenafil or
vardenafil, with no change after treatment with tadalafil. The
level of triglycerides was decreased only by treatment with sil-
denafil. Increased oxidative stress can oxidize HDL to LDL.
In this study, SOD and catalase levels increased in rats given
sildenafil or vardenafil and consequently increased the levels
of oxidative stress. Other studies have also found that en-
hanced HDL levels are due mainly to induction of SOD
and catalase.53
In summary, this study demonstrates that sildenafil and
vardenafil increase the levels of homocysteine, indicating a
possible mechanism for the endothelial dysfunction associated
with hyperhomocysteinaemia. Another important finding of
this study is that ED drugs increase antioxidant properties
by increasing SOD and catalase levels, which can attenuate
the oxidative stress resulting from hyperhomocysteinemia.
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